Stryker Corporation 10-Q Summary: Period Ended June 30, 2006
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2006, and the six-month period ended on that date. Stryker Corporation is a leading medical technology company with operations in Orthopaedic Implants and MedSurg Equipment. The company adopted FASB Statement No. 123 (revised) effective January 1, 2006, requiring the recognition of stock-based compensation expense, which reduced reported operating income and net earnings for the period.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 | Three Months Ended June 30, 2006 |
|---|---|---|---|
| Net Sales | $2,648.8 million | $2,421.1 million | $1,327.9 million |
| Gross Profit | $1,743.4 million (65.8% margin) | $1,568.0 million (64.8% margin) | $875.4 million (65.9% margin) |
| Operating Income | $514.0 million | $487.9 million | $291.9 million |
| Net Earnings | $361.4 million | $344.5 million | $213.9 million |
| Diluted EPS | $0.88 | $0.84 | $0.52 |
| Cash from Operations | $216.5 million | $208.6 million | $195.8 million |
| Cash & Equivalents | $129.7 million | $491.2 million (Dec 31, 2005) | N/A |
| Marketable Securities | $738.0 million | $565.3 million (Dec 31, 2005) | N/A |
| Total Debt | $14.2 million | $231.6 million (Dec 31, 2005) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% year-over-year for both the quarter and the six-month period. Growth was driven by increased unit volume and product mix changes. Domestic sales grew 11% (six months), while international sales grew 6% (reported) or 10% (constant currency).
- Acquisition Impact: The company acquired Sightline Technologies Ltd. in Q1 2006, resulting in a one-time charge of $52.7 million for purchased in-process research and development (IPR&D). This charge reduced operating income and net earnings for the six-month period.
- Accounting Change: Adoption of FASB 123(R) reduced operating income by $29.0 million and net earnings by $18.8 million for the six months ended June 30, 2006, compared to the prior year.
- Profitability: Gross margin improved to 65.8% from 64.8% due to lower excess and obsolete inventory costs. Operating income increased 5% to $514.0 million.
- Liquidity: Cash and cash equivalents decreased significantly from $491.2 million at year-end 2005 to $129.7 million, largely due to debt repayments ($311.6 million) and acquisitions ($79.3 million), partially offset by strong operating cash flow.
Guidance, Outlook, and Risks
- 2006 Outlook: Management projects adjusted diluted net earnings per share of $2.02 for 2006, representing a 21% increase over the prior year. This excludes the $52.7 million Sightline IPR&D charge.
- Sales Forecast: Net sales are expected to increase 11% to 13% for the full year 2006. Foreign currency exchange rates are expected to have an unfavorable impact of 0% to 1% on full-year sales.
- Legal Contingencies: The company is cooperating with multiple Department of Justice investigations regarding billing practices (Physiotherapy Associates), consulting contracts with surgeons, and potential antitrust violations related to orthopaedic implants. No material losses are anticipated beyond amounts already provided.
- Regulatory: The company submitted a pre-market approval application to the FDA for OP-1 Putty for lumbar spine fusion. Adoption of FASB Interpretation No. 48 (Accounting for Uncertainty in Income Taxes) is planned for January 1, 2007.
Investor Verification Checklist
- Adjusted Earnings: Verify the reconciliation of reported net earnings ($361.4M) to adjusted net earnings ($414.1M) by adding back the $52.7 million non-cash IPR&D charge.
- Stock-Based Compensation: Review the impact of the new FASB 123(R) standard on future quarters, noting $162.3 million of unrecognized compensation cost remaining.
- Legal Exposure: Monitor the status of the three active DOJ investigations (billing, consulting, antitrust) for potential fines or settlements.
- Currency Impact: Assess the sensitivity of international sales (35% of total) to foreign exchange fluctuations, which negatively impacted reported growth.
- Inventory Levels: Note the increase in days sales in inventory to 129 days, attributed to stockpiling for anticipated product launches in the second half of the year.